Strasbourg, France, July 10, 2018 – CardioRenal, a major new player in telemedicine for patients with severe heart failure, today announces the arrival of Didier Miraton as an independent member of its supervisory board. Mr. Miraton boasts both substantial life sciences and industrial experience, gained as  CEO of  the Michelin Group and then of Pierre Fabre. He brings his expertise to CardioRenal as the start-up is embarking on a critical phase in its development.

Heart failure is the leading cause of adult hospital admissions in developed countries. CardioRenal has designed a telemedicine device that provides patients with more frequent, personalized monitoring, avoiding traumatic hospital stays that are costly for healthcare systems.

Didier Miraton’s arrival coincides with preparations by CardioRenal to market its device in Europe, Russia and South America, through the joint development and licensing agreement forged in mid-2017 with Servier’s WeHealth by Servier division.

His significant industry experience will be essential for CardioRenal in this phase of development, where the challenges of large-scale industrialization are particularly critical.

“I appreciate the vote of confidence that Didier Miraton has expressed by joining us. I am delighted that CardioRenal will reap the benefits of his experience as we move into this pivotal phase of industrialization,” said Maurice Bérenger, CEO of CardioRenal.

A graduate of Ecole Nationale des Ponts et Chaussées, Didier Miraton began his career in 1982 as a research engineer at Michelin. He then held several posts in France and the US, including as president of Research & Technology and a member of the executive board of the Michelin Group. From 2007 to 2011, he was a managing partner of the Group. In 2012, Miraton was appointed CEO of Laboratoires Pierre Fabre. Today he is a business leader and teaches at the Collège des Ingénieurs graduate school in Paris, France.

 

About CardioRenal

CardioRenal is dedicated to improving treatment at home for severe heart failure patients.

CardioRenal’s telemedicine device is unique. It allows for the daily measurement of three cardiac biomarkers in a droplet of blood drawn by the patient. The readings are taken via a point-of-care minilab developed by CardioRenal and installed in the patient’s home. The data collected is sent to a secure health data center, where it is stored. The treating physician can then access the data and optimize the treatment accordingly, even when the patient’s condition is not stabilized.

Since it was founded in 2013, CardioRenal has received financial backing from the Grand Est Region in France and from the French public investment bank, Bpifrance.

www.cardio-renal.com